Safety of Metformin Continuation During Peri-Procedural Period of Coronary Angiography in Type 2 Diabetic Patients

Dana Hama-Baqi  Mohammed-Saeed

doi:10.56056/403

Authors

Dana Hama-Baqi Mohammed-Saeed Branch of Clinical Sciences, College of Medicine, University of Sulaimani, Sulaimani, Kurdistan Region, Iraq.Department of Cardiology, Sulaimani Cardiac Hospital, Qanat Street, Sulaimani, Kurdistan Region, Iraq

DOI:

https://doi.org/10.56056/403

Keywords:

Angiography, Acute kidney injury, Contrast-induced nephropathy, Lactic acidosis, Renal failure

Abstract

Background The safety of maintaining metformin therapy in patients undergoing coronary angiography is a topic of ongoing debate. The present study aims to examine patients with type 2 diabetes who continued to use metformin while undergoing coronary angiography for the development of contrast-induced nephropathy and lactic acidosis.

Patients and Methods This investigation was a cross-sectional study that was carried out in Sulaimani Cardiac Hospital between January 2023 to June 2023 that enrolled 100 patients with type 2 diabetes and baseline creatinine clearance more than 45 ml/min for whom elective coronary angiography was performed. Monitoring of renal function and clinical signs of lactic acidosis were observed.

Results The majority of cases (57%) received less than 50 cc of contrast, followed by 50-150 cc in 32 cases. Only one patient, a 70-year-old woman with a baseline impaired creatinine level (1.4 mg/dL), developed contrast-induced nephropathy, and there was no statistically significant change in creatinine level. With vigilant monitoring and proper hydration, her renal function returned to baseline levels within 7 days after the angiogram. Furthermore, there was no lactic acidosis in any of the participants.

Conclusion It appears to be safe to continue metformin therapy during coronary angiography for type 2 diabetic patients whose baseline creatinine clearance above 45 ml/min.

Downloads

Download data is not yet available.

References

1. Kumar S, Nair RK, Aggarwal N, Abbot AK, Muthukrishnan J, Kumar KVSH. Risk factors for contrastinduced nephropathy after coronary angiography. Saudi J Kidney Dis Transplant. 2017;28(2):318–24.

2. Nicola R, Shaqdan K, Aran K, Mansouri M, Singh A, Abujudeh H. Contrast-induced nephropathy: identifying the risks, choosing the right agent, and reviewing effective prevention and management methods. Curr Probl Diagn Radiol. 2015;44(6):501-4.

3. Hölscher B, Heitmeyer C, Fobker M, Breithardt G, Schaefer RM, Reinecke H. Predictors for contrast media-induced nephropathy and long-term survival: Prospectively assessed data from the randomized controlled Dialysis-Versus-Diuresis (DVD) trial. Can J Cardiol. 2008;24(11):845–50.

4. Romano G, Briguori C, Quintavalle C, Zanca C, Rivera N V., Colombo A, et al. Contrast agents and renal cell apoptosis. Eur Heart J. 2008;29(20):2569–76.

5. Mehran R, Nikolsky E. Contrast-induced nephropathy: Definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006;69(100): S11-5.

6. Chiarito M, Sanz-Sanchez J, Piccolo R, Condello F, Liccardo G, Maurina M, et al. Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial. Cardiovasc Diabetol. 2023;22(1):28–37.

7. Lu W, Defilippi J, Braun A. Unleash metformin: reconsideration of the contraindication in patients with renal impairment. Ann Pharmacother. 2013;47(11):1488-97.

8. Al-Osali ME, Al-Qassabi SS, Al-Harthi SM. Assessment of glomerular filtration rates by cockcroft-gault and modification of diet in renal disease equations in a cohort of Omani patients. Sultan Qaboos Univ Med J. 2014;14(1):72–9.

9. Bangalore S, Barsness GW, Dangas GD, Kern MJ, Rao S V., Shore-Lesserson L, et al. Evidence-Based Practices in the Cardiac Catheterization Laboratory: A Scientific Statement from the American Heart Association. Circulation. 2021;144(5): E107–19.

10. Rundback JH, Nahl D, Yoo V. Contrast-induced nephropathy. J Vasc Surg. 2011;54(2):575–9.

11. Gleeson T, Bulugahapitiya S. Contrast-induced nephropathy. AJR. 2004;183(6):1673-90.

12. Kellum J, Lameire N, Aspelin P, Barsoum R, Burdmann E, Goldstein S. kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–38.

13. Davenport MS, Khalatbari S, Dillman JR, Cohan RH, Caoili EM, Ellis JH. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material. Radiology. 2013;267(1):94–105.

14. Namazi MH, Parsa SA, Roohigilani K, Safi M, Vakili H, Khaheshi I, et al. Is it necessary to discontinue metformin in diabetic patients with GFR > 60 ml/min per 1.73 m 2 undergoing coronary angiography: A controversy still exists Acta Biomed. 2018;89(2):227–32.

15. Kraut JA, Kurtz I. Treatment of acute non-anion gap metabolic acidosis. Clin Kidney J. 2015;8(1):93–9.

16. H.S. Trivedi, H. Moore, S. Masr, K. Aggarwal, A. Agrawal, P. Goel, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract, 93 (2003), p. 34

17. Pioli MR, Couto RM, Francisco J de A, Antoniassi DQ, de Souza CR, de Olivio MY, et al. Effectiveness of Oral Hydration in Preventing Contrast-Induced Nephropathy in Individuals Undergoing Elective Coronary Interventions. Arq Bras Cardiol. 2023;120(2): e20220529.

18. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165.

19. Rahmanian M, Moradi S, Raziee FM, Dehkordi A, Dehghan S, Ghanbarzadeh E, et al. Risk of lactic acidosis following injection of iodinated contrast medium for individuals with type 2 diabetes receiving metformin during angiography. J Ren Endocrinol. 2023;9: e25083.

20. Muhialdeen AS, Ahmed JA, Baba HO, Abdullah IY, Hassan HA, Najar KA, et al. Kscien’s List; A New Strategy to Discourage Predatory Journals and Publishers (Second Version). Barw Med J. 2023;1(1):24–6.